Lantheus Holdings Inc.
NASDAQ · LNTH·Bedford, MA·Mid-cap·Approved
Radiopharmaceutical company with Pylarify (piflufolastat F18) as a leading PSMA-PET imaging agent for prostate cancer. Lantheus is expanding into therapeutic radiopharmaceuticals and next-generation diagnostic agents across oncology, including its SPLASH platform.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Lantheus Investor Presentation | Corporate overview | January 1, 2026 | 55 |